1. A 54-year-old woman with AML (acute myeloid leukemia) is receiving consolidation chemotherapy through a tunneled central venous catheter. On day 8 of chemotherapy she develops fever and blood cultures drawn through the catheter grow Candida parapsilosis (fluconazole-susceptible). She is started on an echinocandin. The oncology team is reluctant to remove the catheter because it is the only reliable venous access for her ongoing chemotherapy, which cannot be interrupted without risking relapse. Her next chemotherapy dose is scheduled in 4 days. Which of the following best describes the recommended approach to catheter management in this patient?
A) The central venous catheter should be retained because C. parapsilosis candidemia associated with a catheter always resolves with antifungal therapy alone, and the oncological risk of removing the line outweighs the infectious risk of retention in a patient with leukemia
B) Catheter removal should be deferred until the completion of the current chemotherapy cycle; the 14-day antifungal treatment duration is counted from catheter removal, so delaying removal simply extends the planned treatment duration without affecting outcome
C) The central venous catheter should be removed as soon as clinically feasible despite the oncological inconvenience; catheter retention in the setting of candidemia — particularly C. parapsilosis, which is strongly biofilm-associated — prolongs the duration of fungemia, increases the risk of metastatic seeding and endophthalmitis, and is independently associated with increased mortality; alternative venous access should be established and chemotherapy rescheduled rather than the catheter retained
D) The catheter should be retained and the echinocandin changed to fluconazole lock therapy instilled directly into the catheter lumen; intraluminal antifungal lock therapy eradicates biofilm-associated Candida and is the preferred alternative to catheter removal when access is required for active chemotherapy
E) The central venous catheter can be retained safely if repeat blood cultures through the catheter are negative at 48 hours; a single negative culture drawn through the retained catheter confirms biofilm eradication and eliminates the need for line removal
ANSWER: C
Rationale:
Option C is correct. IDSA guidelines recommend central venous catheter removal in all patients with candidemia whenever it is clinically feasible, and this recommendation applies even in patients whose venous access is needed for ongoing therapy. The rationale is pharmacological and microbiological: Candida species — particularly Candida parapsilosis, which has a notably strong propensity for biofilm formation — adhere to catheter surfaces and form organized biofilm communities in which organisms are protected from both antifungal drugs and host immune defenses. Echinocandins and azoles penetrate biofilm poorly; concentrations required to eradicate biofilm-embedded Candida are far above those achievable systemically, meaning that as long as the catheter remains in place, it serves as a continuous reservoir reseeding the bloodstream. Sustained fungemia from a retained catheter is associated with metastatic complications including endophthalmitis, endocarditis, osteomyelitis, and CNS seeding, and independently predicts increased 30-day mortality in multiple prospective cohort analyses. The oncological inconvenience of line removal — however significant — does not outweigh these consequences. The appropriate management is to remove the catheter, establish alternative venous access, and reschedule chemotherapy rather than compromise candidemia treatment.
Option A: Option A is incorrect because C. parapsilosis candidemia does not reliably resolve with antifungals alone when the catheter is retained; its strong biofilm association makes catheter-associated C. parapsilosis particularly resistant to antifungal therapy without source removal.
Option B: Option B is incorrect because the 14-day duration is counted from the last positive blood culture regardless of catheter removal timing; retaining the catheter does not simply extend the clock — it maintains the infectious source and increases the risk of persistent or recurrent fungemia.
Option D: Option D is incorrect because antifungal lock therapy — instillation of a concentrated antifungal solution into the catheter lumen — is not an established alternative to catheter removal for candidemia; it has been evaluated in bacterial catheter-related bloodstream infections but is not recommended as a substitute for line removal in Candida infection.
Option E: Option E is incorrect because a single negative culture drawn through the retained catheter does not confirm biofilm eradication; biofilm-embedded organisms produce intermittent rather than continuous bloodstream seeding, and a negative culture at 48 hours with the catheter in place does not rule out ongoing reservoir infection or future fungemia.
2. A 47-year-old allogeneic stem cell transplant recipient has been on voriconazole for invasive pulmonary aspergillosis for 18 days with good radiological response. Over the past 3 days he has developed vivid visual hallucinations, seeing geometric patterns when he closes his eyes, and episodes of confusion lasting 20 to 30 minutes. His voriconazole trough level is 6.8 mg/L (therapeutic target 1.0–5.5 mg/L). He has no fever, no new CNS imaging abnormalities on MRI, and his Aspergillus galactomannan has declined from 2.1 to 0.3 ODI. Which of the following best describes the correct management of this patient's neurological symptoms?
A) The visual hallucinations and confusion are consistent with voriconazole neurotoxicity at a supratherapeutic trough level of 6.8 mg/L; the voriconazole dose should be reduced to bring the trough into the 1.0 to 5.5 mg/L target range, with repeat level monitoring — discontinuing voriconazole entirely would risk aspergillosis relapse given the ongoing immunosuppression and is not indicated when neurotoxicity is manageable with dose adjustment
B) The visual hallucinations indicate Aspergillus CNS dissemination that has occurred despite adequate voriconazole trough levels; the appropriate response is to add liposomal amphotericin B for CNS penetration and arrange urgent stereotactic brain biopsy to confirm the diagnosis
C) The visual symptoms are caused by voriconazole-induced retinal toxicity from direct drug deposition in the vitreous humor; voriconazole must be discontinued immediately and permanently because retinal toxicity is irreversible and continued therapy carries risk of permanent blindness
D) The confusion and visual hallucinations reflect tacrolimus neurotoxicity from a voriconazole-tacrolimus drug interaction; the appropriate response is to check a tacrolimus trough level and reduce the tacrolimus dose rather than adjusting voriconazole, because the antifungal trough of 6.8 mg/L is within an acceptable extended range for severe aspergillosis
E) The neurological symptoms represent Aspergillus-associated immune reconstitution inflammatory syndrome (IRIS) following engraftment; the appropriate management is corticosteroids to suppress the inflammatory response rather than any change to the antifungal regimen
ANSWER: A
Rationale:
Option A is correct. Voriconazole neurotoxicity — including visual hallucinations, photopsia (flashes and geometric patterns, particularly with eyes closed), encephalopathy, and peripheral neuropathy — is a well-characterized adverse effect that correlates with supratherapeutic drug exposure. The target trough range of 1.0 to 5.5 mg/L reflects both the efficacy floor (below 1.0 mg/L, treatment failure rates rise) and the toxicity ceiling (above 5.5 mg/L, neurotoxicity and hepatotoxicity risk increase substantially). This patient's trough of 6.8 mg/L clearly exceeds the upper boundary and temporally coincides with the onset of neurological symptoms in the absence of any other explanation — the MRI is normal, fever is absent, and galactomannan is declining, arguing against CNS aspergillosis or another infectious process. The correct intervention is dose reduction to bring the trough within the therapeutic window, with repeat level monitoring to confirm the adjustment was adequate; the neurological symptoms typically resolve within days of trough normalization. Discontinuing voriconazole entirely is not warranted when a straightforward dose adjustment addresses the toxicity and the patient is responding to treatment for a life-threatening infection.
Option B: Option B is incorrect because the clinical picture — normal MRI, declining galactomannan, no fever — does not support CNS aspergillosis dissemination; the supratherapeutic voriconazole level is the parsimonious and pharmacologically consistent explanation for the neurological symptoms.
Option C: Option C is incorrect because voriconazole visual symptoms are primarily of CNS origin — affecting visual cortical processing — rather than direct retinal drug toxicity; while voriconazole does reach the vitreous and some photoreceptor effects have been reported, the hallucinations described here are typical of CNS-mediated supratherapeutic voriconazole exposure and do not represent irreversible retinal damage requiring permanent discontinuation.
Option D: Option D is incorrect because while voriconazole does inhibit tacrolimus metabolism via CYP3A4, the supratherapeutic voriconazole trough of 6.8 mg/L is not within any acceptable extended range; the clinical presentation is most consistent with voriconazole neurotoxicity, and the appropriate initial action is dose reduction of voriconazole rather than solely adjusting tacrolimus.
Option E: Option E is incorrect because Aspergillus-associated IRIS following engraftment is a recognized entity, but it is a diagnosis of exclusion that does not explain supratherapeutic voriconazole levels, and initiating corticosteroids without first addressing the pharmacokinetic explanation for the symptoms would be premature and potentially harmful.
3. A 28-year-old HIV-positive man completed 2 weeks of induction therapy with L-AmB plus flucytosine for cryptococcal meningitis, with documented CSF sterilization and clinical improvement. He was started on ART (antiretroviral therapy) 5 weeks after beginning antifungal induction and transitioned to consolidation fluconazole 400 mg daily. His CD4 count has risen from 18 to 94 cells/mm³ over the past 6 weeks on ART. He now presents at week 8 with new-onset severe headache, fever, and neck stiffness. Repeat lumbar puncture shows an opening pressure of 28 cm H₂O, CSF lymphocytic pleocytosis with 84 cells/mm³, elevated protein, and a negative CSF culture. Serum cryptococcal antigen is positive at a titer of 1:32, down from 1:512 at diagnosis. Which of the following best explains this presentation and describes the correct management?
A) The negative CSF culture with positive serum cryptococcal antigen and clinical deterioration indicates antifungal treatment failure due to fluconazole resistance; consolidation therapy should be discontinued and the patient restarted on L-AmB plus flucytosine induction
B) The presentation indicates a new bacterial meningitis superimposed on the treated cryptococcal infection; the lymphocytic pleocytosis and elevated protein reflect residual cryptococcal inflammation and the current episode should be treated with empiric antibacterial coverage
C) The clinical deterioration reflects progressive HIV encephalopathy from ongoing viral replication despite ART; the appropriate response is to check an HIV viral load and modify the antiretroviral regimen rather than changing antifungal therapy
D) The presentation represents fluconazole-induced meningeal inflammation from drug hypersensitivity; fluconazole should be discontinued and the patient observed for 48 to 72 hours to confirm symptom resolution before restarting antifungal consolidation
E) This presentation is consistent with paradoxical cryptococcal immune reconstitution inflammatory syndrome (IRIS), occurring as the recovering immune system mounts an exuberant inflammatory response to residual Cryptococcus antigens following ART-driven CD4 recovery; the negative CSF culture distinguishes IRIS from relapse, and management focuses on ICP control with therapeutic lumbar punctures — corticosteroids may be used for severe IRIS symptoms refractory to ICP management
ANSWER: E
Rationale:
Option E is correct. This clinical presentation is characteristic of paradoxical cryptococcal IRIS (immune reconstitution inflammatory syndrome). The diagnostic features that distinguish paradoxical IRIS from treatment failure or relapse are precisely those present here: the patient previously achieved documented CSF sterilization (confirmed negative culture at end of induction), his cryptococcal antigen titer has declined from 1:512 to 1:32 indicating reduced fungal burden rather than proliferation, the CSF culture is negative, and the clinical deterioration follows a clear temporal pattern of immune recovery — CD4 count rising from 18 to 94 cells/mm³ on ART, with symptoms emerging after substantial immune reconstitution. Paradoxical IRIS occurs when a recovering immune system mounts an amplified inflammatory response against residual Cryptococcus antigens in the CNS after the organism has already been suppressed; this is distinct from unmasking IRIS (which presents as new meningitis in patients starting ART who had subclinical infection). The lymphocytic pleocytosis and elevated protein reflect active CNS inflammation driven by host immunity, not fungal proliferation. Management centers on ICP control through therapeutic lumbar punctures (opening pressure 28 cm H₂O requires drainage to below 20 cm H₂O) and continuation of antifungal therapy. For severe or refractory IRIS manifestations, corticosteroids — despite their general contraindication in active cryptococcal meningitis — may be cautiously used because the harm in established IRIS comes from the inflammatory response rather than unchecked fungal growth.
Option A: Option A is incorrect because treatment failure with fluconazole resistance would be expected to show a rising or persistently positive CSF culture, increasing cryptococcal antigen titers, and absence of the immune recovery context; the declining antigen titer and negative culture are inconsistent with relapse or resistance.
Option B: Option B is incorrect because the CSF profile of lymphocytic pleocytosis without organisms on culture, the declining cryptococcal antigen, and the temporal relationship to ART initiation and immune recovery are not consistent with a new bacterial meningitis; bacterial meningitis typically produces neutrophilic pleocytosis.
Option C: Option C is incorrect because HIV encephalopathy does not explain the focal CSF abnormalities, the elevated opening pressure, or the positive cryptococcal antigen; and the immune reconstitution context directly points to a Cryptococcus-related process.
Option D: Option D is incorrect because fluconazole-induced meningeal hypersensitivity is not a recognized clinical entity; the symptoms and CSF findings are not consistent with drug hypersensitivity, and discontinuing fluconazole during an episode of suspected IRIS would remove the antifungal protection at a time when some residual fungal antigen burden remains.
4. A 58-year-old man with type 2 diabetes was hospitalized 3 weeks ago for severe COVID-19 pneumonia requiring 12 days of dexamethasone 6 mg daily and high-flow oxygen. He was discharged 10 days ago with blood glucose poorly controlled at 280 to 340 mg/dL. He now returns with 5 days of worsening facial pain, periorbital swelling, and a dark eschar on the left hard palate. CT sinuses shows left maxillary and ethmoid opacification with erosion through the medial orbital wall. Tissue biopsy reveals broad aseptate hyphae with right-angle branching. Which of the following represents the correct integrated management approach for this patient?
A) Voriconazole 6 mg/kg IV every 12 hours for two loading doses then 4 mg/kg IV every 12 hours is the preferred first-line antifungal, combined with aggressive glycemic control; surgical debridement should be deferred until antifungal therapy has produced at least 7 to 10 days of radiological stabilization to reduce perioperative bleeding risk from inflamed sinuses
B) Liposomal amphotericin B 5 to 10 mg/kg/day IV is the required first-line antifungal agent; any residual corticosteroid effect should be reversed as rapidly as clinically safe; blood glucose must be aggressively controlled to restore neutrophil function; and surgical debridement of necrotic sinus and orbital tissue must not be deferred — delay is independently associated with mortality
C) Isavuconazole 372 mg IV every 8 hours for 6 loading doses then 372 mg IV once daily is the preferred first-line agent because it has lower nephrotoxicity than liposomal amphotericin B and can be started immediately while surgical planning proceeds over the next 5 to 7 days
D) Caspofungin 70 mg IV loading then 50 mg IV daily is the preferred empiric agent pending formal mycological identification; echinocandins cover a broad range of mold infections and should be initiated before biopsy results are finalized in rapidly progressing rhinocerebral infections
E) Posaconazole delayed-release tablet 300 mg twice daily for 2 days loading then 300 mg once daily is appropriate initial therapy; the oral route is preferred over IV amphotericin B because the patient can swallow and oral bioavailability of the DR tablet is sufficient for rhinocerebral mucormycosis at this stage
ANSWER: B
Rationale:
Option B is correct. This patient has post-COVID-19 rhinocerebral mucormycosis, a devastating complication documented extensively during and after the COVID-19 pandemic — particularly in patients who received corticosteroids and had underlying diabetes or steroid-induced hyperglycemia. The three pillars of management are integrated and all must be pursued simultaneously without delay: antifungal therapy, reversal of predisposing factors, and surgical debridement. For antifungal therapy, liposomal amphotericin B (L-AmB) at 5 to 10 mg/kg/day is the required first-line agent; no other antifungal has equivalent evidence or guideline backing as initial therapy for mucormycosis. For predisposing factor reversal, corticosteroids must be tapered or discontinued as rapidly as clinically safe — dexamethasone was the primary driver of this patient's iatrogenic immunosuppression and both the steroid-induced immune suppression and the resultant hyperglycemia must be corrected; aggressive blood glucose control is specifically critical because DKA and hyperglycemia impair neutrophil oxidative killing and increase free serum iron availability for fungal growth. Surgical debridement must not be deferred: delay in surgery is an independent predictor of mortality in rhinocerebral mucormycosis across multiple large retrospective series, and waiting for antifungal "stabilization" allows progressive angioinvasion into the orbit, skull base, and CNS before debridement.
Option A: Option A is incorrect because voriconazole has no antifungal activity against Mucorales and must never be used for mucormycosis — this is an absolute contraindication; and surgical debridement must not be deferred.
Option C: Option C is incorrect because while isavuconazole is an approved alternative for mucormycosis and has lower nephrotoxicity than L-AmB, it is not the preferred first-line choice over L-AmB in a rapidly progressing presentation, and surgical planning should proceed urgently rather than over 5 to 7 days.
Option D: Option D is incorrect because echinocandins have no activity against Mucorales; caspofungin would provide zero antifungal coverage and its use would constitute dangerous empiric therapy that delays effective treatment while the infection progresses.
Option E: Option E is incorrect because while posaconazole DR tablet achieves adequate oral bioavailability and has activity against Mucorales, it is used for step-down or salvage therapy — not as initial primary therapy replacing L-AmB in a patient with rapidly progressing rhinocerebral mucormycosis with orbital extension.
5. A 51-year-old man with AML is on day 21 of remission-induction chemotherapy and has been receiving posaconazole oral suspension 200 mg three times daily for antifungal prophylaxis. He has developed severe oral mucositis, requires a proton pump inhibitor (PPI) for esophagitis, and has been unable to eat for the past 6 days. He now develops a fever that does not respond to broad-spectrum antibacterials. A chest CT shows a new 2.1 cm right lower lobe nodule with a halo sign. Serum galactomannan ODI is 1.8 on two consecutive samples. A posaconazole trough level returns at 0.28 mcg/mL (target above 0.7 mcg/mL for prophylaxis). Which of the following best describes the contributing pharmacokinetic failure and the correct management response?
A) The posaconazole level of 0.28 mcg/mL reflects CYP3A4 induction by the PPI, which accelerates posaconazole hepatic metabolism; the appropriate response is to discontinue the PPI and recheck the posaconazole level before initiating antifungal treatment
B) The sub-therapeutic posaconazole level results from azole class resistance in the patient's endogenous Aspergillus flora, selected by 3 weeks of prophylaxis exposure; susceptibility testing should be obtained before switching to any alternative azole
C) Posaconazole suspension achieves adequate levels regardless of food intake because it is absorbed through direct mucosal contact with the oral epithelium; the sub-therapeutic level reflects non-adherence and directly observed therapy should be implemented before considering a formulation change
D) The sub-therapeutic posaconazole trough reflects the well-characterized food and gastric acid dependence of posaconazole suspension absorption: mucositis has eliminated oral intake, the PPI has raised gastric pH, and both conditions together have severely reduced drug bioavailability; the suspension should be replaced with either posaconazole IV or the delayed-release (DR) tablet formulation, and antifungal treatment for probable IPA (invasive pulmonary aspergillosis) — most likely with voriconazole or isavuconazole — should be started given the clinical, radiological, and biomarker findings
E) The sub-therapeutic posaconazole level is an acceptable finding during active chemotherapy because neutropenia impairs the pharmacodynamic effect of all antifungals; the appropriate response is to wait for neutrophil recovery before escalating therapy, as antifungal activity is immune-dependent
ANSWER: D
Rationale:
Option D is correct. This case illustrates the well-documented pharmacokinetic vulnerability of posaconazole oral suspension in patients undergoing intensive chemotherapy. The suspension requires two conditions for adequate absorption: co-ingestion of food (preferably a fatty meal) to stimulate bile secretion and solubilize the lipophilic drug, and an acidic gastric environment for drug dissolution. This patient has lost both: severe mucositis has eliminated oral food intake for 6 days, and the PPI has raised gastric pH, further impairing posaconazole dissolution. The result is a trough of 0.28 mcg/mL — less than half the prophylactic target of above 0.7 mcg/mL — representing prophylaxis failure. The clinical consequences are immediately apparent: a new pulmonary nodule with halo sign and galactomannan ODI of 1.8 strongly suggest breakthrough invasive aspergillosis (IPA) that developed despite nominal prophylaxis. The correct response addresses two simultaneous problems: replace the suspension with a formulation that achieves adequate and reliable exposure despite the patient's gastrointestinal state (posaconazole IV or posaconazole DR tablet once mucositis and PPI issues are addressed), and initiate treatment-dose antifungal therapy for probable IPA — most appropriately voriconazole or isavuconazole per IDSA guidelines.
Option A: Option A is incorrect because PPIs do not induce CYP3A4; they raise gastric pH, impairing posaconazole suspension dissolution, but the mechanism is pharmacokinetic (absorption failure), not enzymatic induction — and stopping the PPI would not adequately address the concurrent loss of food intake driving the sub-therapeutic level.
Option B: Option B is incorrect because azole resistance in endogenous Aspergillus flora is not developed or selected within 3 weeks of prophylaxis exposure through a patient's own colonizing organisms; the sub-therapeutic level reflects an absorption failure mechanism that is entirely pharmacokinetic, not resistance-based.
Option C: Option C is incorrect because posaconazole suspension is not absorbed through direct mucosal contact; it requires intestinal absorption dependent on gastric acid and bile, and mucositis-related inability to eat and co-administration of a PPI are established causes of sub-therapeutic levels, not evidence of non-adherence.
Option E: Option E is incorrect because antifungal activity against Aspergillus is not primarily immune-dependent in the pharmacodynamic sense; while neutrophil recovery contributes to overall clinical outcomes, antifungal drugs exert direct fungicidal or fungistatic activity on Aspergillus regardless of immune status, and waiting for neutrophil recovery without escalating antifungal therapy in probable IPA carries high mortality risk.
6. A 36-year-old HIV-positive man is on day 9 of induction therapy with liposomal amphotericin B 3.5 mg/kg/day plus flucytosine (5-FC) 25 mg/kg every 6 hours for cryptococcal meningitis. His clinical status is improving and he is tolerating therapy. His baseline creatinine was 0.8 mg/dL; today it is 2.1 mg/dL (estimated CrCl 38 mL/min, down from 95 mL/min at baseline). A 5-FC trough level is 118 mcg/mL (target 20–100 mcg/mL). His white blood cell count is trending downward at 2,600/mm³. Which of the following best describes the correct adjustment to the 5-FC regimen given these findings?
A) Flucytosine should be discontinued entirely and not restarted for the remainder of the induction course; the combination of supratherapeutic 5-FC levels and a rising creatinine indicates that the drug's risk-benefit ratio has become unfavorable and L-AmB monotherapy should complete the induction phase
B) The 5-FC dose per administration should be increased to 37.5 mg/kg to compensate for the reduced renal clearance, because higher individual doses offset the reduced number of daily doses when the dosing interval must be extended
C) The 5-FC dosing interval should be extended based on the current creatinine clearance — at a CrCl of 38 mL/min, extending from every 6 hours to every 12 hours is the appropriate adjustment; the drug should not be discontinued because the combination of amphotericin B plus 5-FC produces faster CSF sterilization than monotherapy and loss of 5-FC activity at this point in induction compromises the pharmacological rationale for the combination
D) No dose adjustment is required because flucytosine dosing is not affected by renal function; the sub-therapeutic white blood cell count reflects normal variability in HIV-positive patients and the trough of 118 mcg/mL is within an acceptable extended range when the benefit of combination therapy is considered
E) Liposomal amphotericin B should be discontinued and replaced with fluconazole 800 mg daily to eliminate the nephrotoxic driver of 5-FC accumulation; once creatinine normalizes on fluconazole-based therapy, 5-FC can be restarted at the original every-6-hour interval
ANSWER: C
Rationale:
Option C is correct. Flucytosine (5-FC) is eliminated almost entirely by glomerular filtration, meaning that renal impairment — in this case from L-AmB nephrotoxicity — directly reduces 5-FC clearance and causes drug accumulation. The appropriate dose adjustment for renally impaired patients receiving 5-FC is to extend the dosing interval rather than reduce the dose per administration; this maintains peak concentrations adequate for antifungal activity while reducing time-averaged exposure and the cumulative 5-FU generation responsible for myelosuppression. At a CrCl of approximately 38 mL/min, extending the interval from every 6 hours to every 12 hours is a commonly used adjustment, with the trough level serving as the primary guide to confirm that the adjustment has brought exposure into the therapeutic range of 20 to 100 mcg/mL. Critically, 5-FC should not be discontinued: the combination of L-AmB plus 5-FC produces faster CSF sterilization and lower early mortality than L-AmB monotherapy, as established in the ACTA trial and multiple preceding randomized studies. Discontinuing 5-FC partway through induction removes its independent contribution to fungicidal activity at a critical time when CSF sterilization determines early outcomes. The mildly decreasing white blood cell count reinforces the need for dose adjustment but does not mandate 5-FC withdrawal.
Option A: Option A is incorrect because discontinuing 5-FC entirely deprives the patient of the combination benefit that drives the WHO recommendation for L-AmB plus 5-FC; the appropriate response to accumulation is interval adjustment, not drug withdrawal, unless toxicity is severe and unmanageable.
Option B: Option B is incorrect because increasing the dose per administration would worsen 5-FC accumulation and toxicity; in renal impairment, the total daily dose must be reduced (by extending the interval), not increased — raising individual doses in a patient who is already accumulating 5-FC would accelerate hematotoxicity.
Option D: Option D is incorrect because flucytosine dosing is critically dependent on renal function; the 5-FC trough of 118 mcg/mL clearly exceeds the upper target boundary of 100 mcg/mL, and the declining white blood cell count is consistent with early 5-FC myelosuppression requiring proactive dose adjustment rather than observation.
Option E: Option E is incorrect because discontinuing L-AmB and replacing it with fluconazole 800 mg during the induction phase would substantially reduce the fungicidal activity of the regimen; fluconazole-based induction is a fallback when IV amphotericin is unavailable, not a substitution made to protect 5-FC dosing — and the appropriate solution is 5-FC interval adjustment, not removal of the more potent induction agent.
7. A 74-year-old man with a prolonged ICU stay following cardiac surgery develops Candida auris candidemia. He is started on micafungin 100 mg IV daily. Blood cultures initially clear by day 4. On day 12, he re-develops fever and blood cultures again grow C. auris. Repeat susceptibility testing shows an echinocandin MIC of 4 mcg/mL (up from 0.5 mcg/mL at baseline), meeting criteria for echinocandin resistance. Fluconazole MIC is above 64 mcg/mL (resistant), and amphotericin B MIC is 2 mcg/mL. No other antifungal susceptibility results are available. Which of the following best describes the appropriate next steps in management?
A) Early infectious disease specialist consultation and referral to a reference mycology laboratory for expanded susceptibility testing — including testing against novel antifungal agents such as ibrexafungerp or rezafungin if available — is urgently required; pan-resistant C. auris with echinocandin resistance emerging on therapy represents a critical situation for which no single standard-of-care salvage agent exists, and individual susceptibility data and specialist guidance are essential before committing to any empiric agent change
B) The patient should be switched to high-dose fluconazole 800 mg IV daily because the echinocandin resistance is limited to the FKS enzyme target and does not affect azole binding to CYP51; high-dose azole therapy overcomes the fluconazole MIC of above 64 mcg/mL in C. auris through a pharmacokinetic override effect
C) Amphotericin B deoxycholate should be started at 1 mg/kg/day immediately without further susceptibility data; the MIC of 2 mcg/mL is within the susceptible range for all Candida species and standard dosing reliably achieves tissue concentrations above this threshold in all compartments
D) The patient should be switched to voriconazole 4 mg/kg IV every 12 hours because C. auris typically retains voriconazole susceptibility even when echinocandin and fluconazole resistance are present, and voriconazole's fungicidal activity against resistant Candida strains has been established in multiple randomized trials
E) No antifungal change is required; echinocandin resistance in C. auris is always transient and MIC elevations observed during therapy represent phenotypic plasticity rather than true genetic resistance, reverting to susceptible on drug withdrawal — the patient should continue micafungin and the elevated MIC result should be disregarded
ANSWER: A
Rationale:
Option A is correct. This patient has developed C. auris candidemia with emergent echinocandin resistance during micafungin therapy — an FKS gene mutation has been selected during treatment, raising the MIC from 0.5 to 4 mcg/mL. Combined with high-level fluconazole resistance, this patient effectively has C. auris resistant to both major first-line antifungal classes. The amphotericin B MIC of 2 mcg/mL is in the intermediate to resistant range for C. auris depending on the interpretive criteria applied, and the clinical evidence for AmB efficacy in C. auris with elevated MICs is limited. This situation represents one of the most challenging scenarios in clinical mycology: pan-resistant or near-pan-resistant C. auris with no clearly effective standard-of-care salvage agent. The appropriate response is urgent infectious disease specialist consultation combined with referral to a reference mycology laboratory capable of testing against newer antifungal agents. Novel antifungals with distinct mechanisms — including ibrexafungerp (a triterpenoid glucan synthase inhibitor with a different binding site from echinocandins, potentially retaining activity against FKS-mutant strains) and rezafungin (an extended-half-life echinocandin) — may retain activity against some echinocandin-resistant C. auris, but individual isolate susceptibility data must guide their use. Committing to any agent change without expanded susceptibility data would be empirically unsupported.
Option B: Option B is incorrect because a fluconazole MIC above 64 mcg/mL indicates high-level resistance; no pharmacokinetic override exists — increasing the dose does not generate blood concentrations sufficient to overcome resistance at this MIC level, and high-dose fluconazole in this context would provide no antifungal benefit.
Option C: Option C is incorrect because an amphotericin B MIC of 2 mcg/mL for C. auris is not clearly within the susceptible range; C. auris has documented amphotericin B resistance in specific clades, MIC interpretive breakpoints for C. auris are not fully standardized, and standard dosing does not reliably achieve concentrations above 2 mcg/mL in all tissue compartments — initiating AmB without further reference laboratory interpretation would be premature.
Option D: Option D is incorrect because voriconazole does not have established or reliably predictable activity against C. auris; C. auris often demonstrates reduced or variable susceptibility to voriconazole, and no randomized trial evidence supports voriconazole as a standard salvage agent for echinocandin-resistant C. auris.
Option E: Option E is incorrect because FKS gene mutations conferring echinocandin resistance in C. auris are genuine genetic mutations — not reversible phenotypic plasticity; once an FKS mutation is selected, it persists and the resistance is durable, not transient, on drug withdrawal.
8. A 29-year-old woman at 11 weeks of gestation presents with cough, fever, weight loss, and night sweats. She lives in Arizona and recently underwent construction work at her home. Chest CT shows bilateral nodular infiltrates. Serum Coccidioides IgM and IgG are positive and serum complement fixation titer is 1:32. Bronchoalveolar lavage culture grows Coccidioides immitis. She has no CNS symptoms and no evidence of dissemination beyond the lungs, but her oxygen saturation is 91% on room air and the infectious disease team considers this moderate-to-severe primary pulmonary coccidioidomycosis requiring systemic antifungal therapy. Which of the following best describes the antifungal approach in this patient given her pregnancy?
A) Fluconazole 400 mg orally once daily is the preferred treatment for coccidioidomycosis in pregnancy because it achieves reliable systemic and fetal tissue concentrations, ensuring adequate drug delivery to both the mother and any potential fetal infection; azole use in pregnancy is approved by major guidelines
B) Voriconazole 200 mg twice daily is preferred over fluconazole in pregnancy because its CYP2C19-mediated metabolism reduces placental drug transfer compared to fluconazole, protecting the fetus while maintaining maternal therapeutic levels
C) No antifungal therapy is required during the first trimester; treatment should be deferred until 14 weeks of gestation regardless of disease severity because all systemic antifungals are contraindicated in the first trimester and supportive care alone is the standard until organogenesis is complete
D) Itraconazole oral solution 200 mg twice daily is the safest azole for use in pregnancy and is the recommended first-line agent for coccidioidomycosis in pregnant women; its higher molecular weight limits placental transfer compared to fluconazole
E) Amphotericin B — preferably liposomal formulation to reduce maternal nephrotoxicity — is the preferred antifungal for coccidioidomycosis during pregnancy, particularly in the first and second trimesters; all azole antifungals including fluconazole, itraconazole, and voriconazole carry teratogenic risk and are generally avoided during pregnancy, especially in the first trimester
ANSWER: E
Rationale:
Option E is correct. Coccidioidomycosis in pregnancy is a clinically dangerous scenario because the altered immune environment of pregnancy — particularly cell-mediated immune suppression — predisposes to dissemination, and disseminated coccidioidomycosis in pregnancy carries high maternal and fetal mortality. When systemic antifungal therapy is required, amphotericin B (preferably liposomal formulation to reduce nephrotoxicity) is the preferred agent because it has a relatively reassuring safety record in pregnancy: it does not cross the placenta in clinically significant concentrations, has been used throughout pregnancy without evidence of teratogenicity in available case series, and does not cause the developmental abnormalities associated with azoles. Azole antifungals — including fluconazole, itraconazole, voriconazole, and posaconazole — are associated with teratogenic risk, particularly when used in the first trimester during organogenesis. Fluconazole at high doses (400 mg or above daily) has been associated with a recognizable pattern of fetal malformations in case reports and pharmacoepidemiological studies. Voriconazole and itraconazole also carry FDA pregnancy category D or X designations (under older classification) based on animal teratogenicity data. For this patient at 11 weeks of gestation with moderate-to-severe pulmonary disease, amphotericin B is the appropriate choice. After delivery, transition to oral azole therapy (typically fluconazole) for completion of treatment and suppression is appropriate.
Option A: Option A is incorrect because fluconazole is specifically associated with teratogenic risk when used at doses of 400 mg or above during organogenesis, and IDSA guidelines for coccidioidomycosis recommend amphotericin B rather than azoles during pregnancy, particularly in the first and second trimesters.
Option B: Option B is incorrect because voriconazole has animal teratogenicity data and carries FDA pregnancy warnings; the suggestion that CYP2C19-mediated metabolism reduces placental transfer in a clinically protective way is not supported by pharmacological data or clinical guidelines.
Option C: Option C is incorrect because no antifungal therapy is not appropriate for moderate-to-severe coccidioidomycosis with hypoxemia at any gestational age; deferring treatment risks maternal respiratory failure, dissemination, and death — the risks of untreated severe fungal infection outweigh the risks of amphotericin B therapy.
Option D: Option D is incorrect because itraconazole is not considered the safest azole in pregnancy; it has documented teratogenicity in animal models and FDA pregnancy warnings, and it is not recommended as the preferred agent for coccidioidomycosis in pregnancy in IDSA guidelines.
9. A 44-year-old HIV-positive man completed 2 weeks of L-AmB induction for severe disseminated histoplasmosis and was transitioned to itraconazole 200 mg twice daily 6 weeks ago. He has been clinically stable and his urine Histoplasma antigen had declined from 14.2 ng/mL at diagnosis to 2.1 ng/mL at his 4-week follow-up. Today at his 10-week visit, his antigen has risen to 4.8 ng/mL. He reports taking itraconazole capsules consistently with breakfast. He has had no new symptoms. His HIV viral load remains undetectable on ART. Which of the following is the most important first step in evaluating this antigen rise before concluding that histoplasmosis relapse has occurred?
A) A repeat urine Histoplasma antigen should be sent to a different reference laboratory because inter-laboratory variation in antigen assay standardization is the most common cause of rising antigen values during apparently adequate itraconazole therapy
B) An itraconazole serum trough level should be obtained; sub-therapeutic itraconazole exposure from inadequate capsule absorption — related to food content, gastric acid, or formulation factors — is a common and correctable cause of rising antigen values that must be excluded before concluding that clinical relapse or resistance has occurred
C) A bone marrow biopsy should be performed immediately to document histological relapse because rising urine Histoplasma antigen above 3.0 ng/mL during therapy is pathognomonic for treatment-refractory disseminated histoplasmosis requiring a return to L-AmB induction
D) The itraconazole dose should be empirically doubled to 400 mg twice daily without checking a drug level; rising antigen during consolidation therapy always reflects sub-therapeutic dosing and the clinical response to dose escalation will confirm whether pharmacokinetic failure was the cause
E) No action is required at this visit; a urine Histoplasma antigen of 4.8 ng/mL during step-down therapy represents expected assay variability within the normal range of fluctuation, and antigen values are not clinically meaningful until they exceed three times the baseline value
ANSWER: B
Rationale:
Option B is correct. Urine Histoplasma antigen is both sensitive for active disseminated histoplasmosis and valuable for monitoring treatment response; a rising antigen level during apparently adequate therapy is a significant finding that must be systematically evaluated before attributing it to clinical relapse. The most important and actionable first step is to check an itraconazole serum trough level, because sub-therapeutic itraconazole exposure is by far the most common correctable cause of apparent antigen rises during step-down therapy. Itraconazole capsule bioavailability has the well-characterized pharmacokinetic requirements of gastric acid and dietary fat co-ingestion, and patients who take capsules consistently without adequate food intake — or who have reduced gastric acid production from PPI use, atrophic gastritis, or other causes — frequently achieve sub-therapeutic levels despite apparent adherence. A trough below 1.0 mcg/mL is considered inadequate for histoplasmosis treatment. In this patient, the report of consistent morning dosing with breakfast is reassuring but not definitive: "breakfast" may be light and low-fat, insufficient to optimize itraconazole absorption, or other factors may be contributing. Confirming an adequate itraconazole level before escalating therapy, changing agents, or performing invasive procedures is the pharmacologically sound approach. If the trough is adequate, further evaluation for relapse — repeat antigen, blood or bone marrow cultures, reassessment of immune status — is then warranted.
Option A: Option A is incorrect because inter-laboratory antigen assay variation is a real consideration but is not the most important first step when a simple pharmacokinetic explanation (sub-therapeutic drug level) is immediately testable and clinically actionable; checking a drug level takes priority over changing laboratories.
Option C: Option C is incorrect because a rising urine antigen during therapy is not pathognomonic for relapse requiring immediate invasive confirmation; it is a monitoring signal that requires stepwise evaluation starting with pharmacokinetic assessment, and bone marrow biopsy is an invasive procedure reserved for situations where non-invasive workup is insufficient.
Option D: Option D is incorrect because empirically doubling the itraconazole dose without first establishing whether the current dose is achieving therapeutic levels would be irrational; if the trough is adequate (above 1.0 mcg/mL), doubling the dose would not improve efficacy and would increase toxicity risk, and the clinical response to empiric dose escalation is an unreliable surrogate for systematic pharmacokinetic evaluation.
Option E: Option E is incorrect because a rise from 2.1 to 4.8 ng/mL during antifungal consolidation is more than a doubling and is clinically significant; urine Histoplasma antigen does not have a defined "normal range of fluctuation" that makes a 128% increase unremarkable, and no validated threshold of "three times baseline" exists as the action threshold during active therapy monitoring.
10. A 33-year-old HIV-positive man was treated for cryptococcal meningitis 18 months ago. He completed induction and consolidation and has been on fluconazole 200 mg daily maintenance therapy since. He has been on effective ART (antiretroviral therapy) for 14 months; his most recent CD4 count is 218 cells/mm³ and has been above 100 cells/mm³ consistently for the past 11 months. His HIV viral load has been undetectable (below 50 copies/mL) for the past 13 months. He remains asymptomatic with no new neurological complaints. He asks his physician whether he can stop the daily fluconazole. Which of the following correctly identifies whether the criteria for safe discontinuation of cryptococcal maintenance therapy have been met in this patient?
A) Maintenance fluconazole cannot be discontinued in HIV-positive patients regardless of CD4 recovery or duration of ART because Cryptococcus neoformans establishes latent CNS infection that requires lifelong suppression analogous to the principle applied to coccidioidal meningitis
B) Maintenance fluconazole can be discontinued when the patient has been asymptomatic for 12 months, regardless of CD4 count or viral load; symptom-based rather than immunological criteria are the most clinically reliable indicators of safe discontinuation
C) Maintenance fluconazole can be discontinued when the CD4 count exceeds 200 cells/mm³ on two consecutive measurements taken 3 months apart, regardless of how long the patient has been on ART or whether the viral load is undetectable
D) This patient meets the criteria for safe discontinuation of fluconazole maintenance therapy: he has received effective ART for more than 1 year, his CD4 count has been sustained above 100 cells/mm³ for more than 6 months, and his HIV viral load is undetectable — these three conditions together indicate sufficient immune reconstitution to prevent cryptococcal relapse, and discontinuation of maintenance therapy is appropriate
E) Maintenance fluconazole can be discontinued only after a repeat lumbar puncture confirms a negative CSF culture and undetectable cryptococcal antigen titer in the CSF; immunological criteria alone are insufficient and microbiological documentation of CSF sterilization must be confirmed before stopping suppressive therapy
ANSWER: D
Rationale:
Option D is correct. Guidelines for discontinuation of cryptococcal maintenance (suppressive) therapy in HIV-positive patients are based on immunological and virological criteria that reflect reconstitution of the immune defenses required to prevent cryptococcal relapse. The IDSA guidelines for cryptococcal disease specify that maintenance fluconazole can be safely discontinued when all of the following conditions are met: the patient has received effective ART for at least 1 year, the CD4 count has been sustained above 100 cells/mm³ for at least 6 months (some guidelines specify above 100 for at least 6 months with consistent measurements), and the HIV viral load is suppressed to undetectable. This patient satisfies all three criteria: ART has been ongoing for 14 months, CD4 has been consistently above 100 cells/mm³ for 11 months, and viral load has been undetectable for 13 months. Importantly, cryptococcal maintenance discontinuation criteria differ from coccidioidal meningitis, where lifelong therapy is required regardless of immune status — Cryptococcus maintenance can be safely stopped in patients with documented immune reconstitution because the risk of relapse falls to acceptably low levels once CD4-dependent immune control is restored.
Option A: Option A is incorrect because cryptococcal and coccidioidal meningitis have fundamentally different suppressive therapy requirements; coccidioidal meningitis requires lifelong therapy because Coccidioides can reactivate regardless of immune status, whereas cryptococcal maintenance can be safely discontinued in HIV-positive patients who achieve and sustain immune reconstitution, as validated in prospective studies.
Option B: Option B is incorrect because symptom-based criteria alone are insufficient for safe discontinuation decisions; asymptomatic status reflects absence of current disease but does not confirm adequate immune reconstitution to prevent future relapse — the immunological and virological criteria are the validated safety thresholds.
Option C: Option C is incorrect because a CD4 count above 200 cells/mm³ on two measurements alone is not the established criterion; the full criteria require CD4 above 100 cells/mm³ sustained for at least 6 months plus viral suppression plus at least 1 year of effective ART — a CD4 threshold of 200 is not the specified cutoff and ART duration and viral suppression are required components.
Option E: Option E is incorrect because repeat lumbar puncture confirming negative CSF culture and undetectable cryptococcal antigen is not a required component of the discontinuation criteria in current guidelines; the immunological and virological criteria have been validated in prospective studies as sufficient, and routinely performing LP before maintenance discontinuation in asymptomatic patients with good immune reconstitution is not standard practice.
11. A 67-year-old man with type 2 diabetes, uncontrolled hyperglycemia, and pre-existing stage 4 chronic kidney disease (CrCl 22 mL/min) is diagnosed with rhinocerebral mucormycosis. The infectious disease team wants to initiate liposomal amphotericin B, but the nephrology team is concerned that even liposomal formulation carries significant risk of pushing the patient to dialysis given his severely reduced renal reserve. Which of the following best describes the role of isavuconazole in this clinical scenario and the evidence supporting its use?
A) Isavuconazole is not appropriate for mucormycosis because it is a triazole class agent and all triazoles lack activity against Mucorales; only amphotericin B formulations provide clinically meaningful antifungal activity against this pathogen, and the nephrotoxicity risk must be accepted as an unavoidable trade-off
B) Isavuconazole cannot be used in patients with CrCl below 30 mL/min because the drug undergoes extensive renal elimination and accumulates to toxic levels in severe renal impairment; fluconazole should be substituted as the renally safe azole alternative for mucormycosis
C) Isavuconazole is an appropriate primary therapy alternative for mucormycosis when liposomal amphotericin B poses unacceptable toxicity risk; it demonstrated non-inferiority to L-AmB in an open-label trial for mucormycosis and mold infections, is primarily eliminated by hepatic metabolism without significant renal accumulation, and has a substantially better renal safety profile — making it the most clinically appropriate antifungal choice when L-AmB use is limited by pre-existing renal disease
D) Isavuconazole can be used as primary therapy for mucormycosis only when posaconazole has first been tried and failed; guidelines require a mandatory sequential therapeutic trial of posaconazole before isavuconazole is eligible as an alternative to amphotericin B
E) Isavuconazole should be reserved for salvage therapy in mucormycosis that has failed at least 4 weeks of L-AmB treatment; using it as initial therapy is not supported by any clinical data and represents an off-label use without guideline backing
ANSWER: C
Rationale:
Option C is correct. Isavuconazole is a licensed and guideline-supported treatment option for mucormycosis. Unlike voriconazole, which has no activity against Mucorales, isavuconazole demonstrates established activity against organisms in the order Mucorales and is the only azole class agent with regulatory approval for this indication. The clinical evidence for isavuconazole in mucormycosis is based primarily on a prospective open-label single-arm trial and a retrospective matched case analysis by Marty et al., in which outcomes with isavuconazole were non-inferior to those with L-AmB-based therapy for primary treatment of mucormycosis and other mold infections. Isavuconazole undergoes primarily hepatic metabolism (via CYP3A4 and esterase-mediated prodrug hydrolysis) with negligible renal elimination; it does not require dose adjustment for renal impairment, does not accumulate in severe renal disease, and does not cause nephrotoxicity. In this patient with a CrCl of 22 mL/min, isavuconazole represents the most clinically appropriate antifungal agent when L-AmB poses an unacceptable risk of dialysis-precipitating nephrotoxicity. The critical accompanying management remains surgical debridement and glycemic optimization — antifungal selection does not replace these.
Option A: Option A is incorrect because isavuconazole is specifically distinguished from other triazoles by having established anti-Mucorales activity; its spectrum uniquely among licensed azoles covers Mucorales, and the assertion that all triazoles lack Mucorales activity incorrectly conflates isavuconazole with voriconazole.
Option B: Option B is incorrect because isavuconazole undergoes primarily hepatic, not renal, metabolism and does not accumulate in renal impairment; no dose adjustment for renal function is required, and this is one of the pharmacokinetic advantages that makes it particularly appropriate in this patient.
Option D: Option D is incorrect because no guideline requires a mandatory trial of posaconazole before isavuconazole can be used for mucormycosis; both are recognized treatment options for mucormycosis (posaconazole for step-down or salvage, isavuconazole for primary or salvage), and no mandatory sequential trial requirement exists in current IDSA or ESCMID guidelines.
Option E: Option E is incorrect because isavuconazole is an approved and guideline-supported primary therapy option for mucormycosis, not a salvage-only agent; its use as initial therapy is supported by clinical data and is specifically listed in IDSA guidelines as an alternative to L-AmB for primary treatment.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.